FDA’s Clinical Investigator Course

Clinical Discussion of Specific Populations

Ryan P. Owen, Ph.D.
Office of Clinical Pharmacology
Office of Translational Sciences
Center for Drug Evaluation & Research
One Size Does Not Fit All
Common Inclusion/Exclusion Criteria

- **Age**
  - Lower bound typically 18 years
  - Upper bound often 55-65 years

- **Pregnancy**
  - Also women who could possibly become pregnant

- **BMI**
  - Typically capped at 25-30 kg/m²
# Phase 1 versus Phase 3 Demographics

<table>
<thead>
<tr>
<th>Demographic Factor</th>
<th>Phase 1 subjects</th>
<th>Phase 3 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Usually 18-40</td>
<td>Higher % of older patients</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Excluded</td>
<td>Excluded</td>
</tr>
<tr>
<td>Race</td>
<td>Predominantly Caucasian</td>
<td>All Races</td>
</tr>
<tr>
<td>Renal/Hepatic Function</td>
<td>Normal</td>
<td>Often have at least minor degrees of impairment</td>
</tr>
<tr>
<td>Weight</td>
<td>BMI usually lower than 25 kg/m²</td>
<td>Greater % of obese</td>
</tr>
</tbody>
</table>
Factors Contributing to Different Clinical Responses

- Age
- Pregnancy
- Body Composition
- Renal Function
- Diet
- Metabolic Differences
- Genetic Differences
- Concomitant Drugs
- Hepatic Function
- Co-morbidities
Factors Contributing to Different Clinical Responses

- Age
- Pregnancy
- Body Composition
- Renal Function
- Diet
- Metabolic Differences
- Genetic Differences
- Concomitant Drugs
- Hepatic Function
- Co-morbidities
What % of US Population is Typically Excluded?

- Figures from 2010 US Census and CIA World Factbook
  - Total US Population: 308,745,538
  - Under age 18: 74,181,467
  - Over age 65: 40,267,984
  - Estimated population of pregnant women at any given time: 3,302,684
  - Total of 117,752,135
What % of US Population is Typically Excluded?

- Figures from 2010 US Census and CIA World Factbook
  - Total US Population: 308,745,538
  - Under age 18: 74,181,467
  - Over age 65: 40,267,984
  - Estimated population of pregnant women at any given time: 3,302,684
  - Total of 117,752,135

38% of the US Population: more than the combined populations of CA, TX, NY, FL, and IL
Renal Function Changes with Age

Table 24. Normal GFR in Children and Young Adults

<table>
<thead>
<tr>
<th>Age (Sex)</th>
<th>Mean GFR ± SD (mL/min/1.73 m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 week (males and females)</td>
<td>40.6 ±14.8</td>
</tr>
<tr>
<td>2–8 weeks (males and females)</td>
<td>65.8 ±24.8</td>
</tr>
<tr>
<td>&gt;8 weeks (males and females)</td>
<td>95.7 ±21.7</td>
</tr>
<tr>
<td>2–12 years (males and females)</td>
<td>133.0 ±27.0</td>
</tr>
<tr>
<td>13–21 years (males)</td>
<td>140.0 ±30.0</td>
</tr>
<tr>
<td>13–21 years (females)</td>
<td>126.0 ±22.0</td>
</tr>
</tbody>
</table>

*Data based on three studies.\(^{69-71}\)

Abbreviation: SD, standard deviation

Data taken from National Kidney Foundation KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
Hepatic Function Changes with Age

<table>
<thead>
<tr>
<th></th>
<th>Neonates/Infant</th>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal</td>
<td>↓</td>
<td>⇐</td>
<td>⇐</td>
</tr>
<tr>
<td>Metabolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP</td>
<td>↓</td>
<td>↑</td>
<td>⇐</td>
</tr>
<tr>
<td>UGT</td>
<td>↓</td>
<td>⇐</td>
<td>⇐</td>
</tr>
<tr>
<td>Albumin</td>
<td>⇐</td>
<td>⇐</td>
<td>⇐</td>
</tr>
</tbody>
</table>

CYP, cytochrome P450; UGT, uridine diphosphate, glucuronosyl transferase.

Ref: Gail Anderson *Epilepsia* 2002 43(Supp 3) pp 53-59

<table>
<thead>
<tr>
<th>Age group</th>
<th>Number of patients</th>
<th>Mean or median plasma clearance (ml/min/kg)</th>
<th>Range</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm neonates</td>
<td>24</td>
<td>1.8</td>
<td>0.7–6.7</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>?</td>
<td>1.2</td>
<td>?</td>
<td>17</td>
</tr>
<tr>
<td>Term neonates</td>
<td>?</td>
<td>1.8</td>
<td>?</td>
<td>17</td>
</tr>
<tr>
<td>Infants 1–24 months</td>
<td>25</td>
<td>3.0</td>
<td>0.5–25.8</td>
<td>18</td>
</tr>
<tr>
<td>Children 2–11 years</td>
<td>12</td>
<td>9.2</td>
<td>0.5–66.7</td>
<td>18</td>
</tr>
<tr>
<td>Adolescents 12–17 years</td>
<td>20</td>
<td>10.0</td>
<td>?</td>
<td>19</td>
</tr>
</tbody>
</table>

Ref: de Wildt et al *Paediatric and Perinatal Drug Therapy* 2003 5 (3) pp 101-106
Hepatic Metabolism is also Variable

- Expression also influenced by diet and exposure to environmental toxins
- Several common CYP 450 enzymes are polymorphic (2D6, 2C9, 2C19)
- Phase 2 enzymes (e.g. UGT family)
Pediatrics

- A lot of information and guidance from FDA
- Vulnerable Population – can’t consent
- Laws address public health importance for pediatric therapies
  - Established regulations (BPCA and PREA)
  - Entire programs in FDA and other HHS

"Is there a need for this product to be developed for use in children?"
Are Kids Just Small Adults? Not Exactly.

- **Absorption**
  - Gastric acidity, gastric emptying, surface area of absorption

- **Distribution**
  - Changes in body composition, total body water, adipose tissue, protein binding

- **Metabolism**
  - Differential expression of metabolic enzymes

- **Excretion**
  - GFR, tubular secretion and tubular reabsorption can mature at different rates

- **Other Factors**
  - Differences in immune response, CNS development, vital signs, lab values
Example - Argatroban

- Anticoagulant for heparin induced thrombocytopenia
- Predominantly excreted in feces, but also a urinary component
- Metabolized by CYP3A4/5 (metabolites not as potent)
- Dose initially studied in neonates led to increase in serious bleeding
- PK analysis showed need for decreased dose in neonates due to lower hepatic metabolism

## Example - Linezolid

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Cmax (μg/mL)</th>
<th>AUC (μg*h/mL)</th>
<th>CL (mL/min/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre term neonate</td>
<td>12.7</td>
<td>108</td>
<td>2.0</td>
</tr>
<tr>
<td>Full term neonate</td>
<td>11.5</td>
<td>55</td>
<td>3.8</td>
</tr>
<tr>
<td>Infant (1-3 month)</td>
<td>11.0</td>
<td>33</td>
<td>5.4</td>
</tr>
<tr>
<td>3 months – 11 years</td>
<td>15.1</td>
<td>58</td>
<td>3.8</td>
</tr>
<tr>
<td>12-17</td>
<td>16.7</td>
<td>95</td>
<td>2.1</td>
</tr>
<tr>
<td>Adult</td>
<td>12.5</td>
<td>91</td>
<td>1.7</td>
</tr>
</tbody>
</table>

Administered dose: 10 mg/kg or 600 mg (adults and adolescents)
Approach to Pediatric Studies

- Children cannot consent to participate in clinical trials.
- No such thing as a "healthy volunteer"
- Children enrolled in trial must have the potential for direct benefit.

FDA Regulations
Protection of Human Subjects
21 CFR 50

Subpart A: General Provisions
Subpart B: Informed Consent
Subpart D: Safeguards for Children in Clinical Investigations
Approach to Pediatric Studies

- What is the safety knowledge from adult use?
  - Phase 1, 2, 3 studies in adults may provide evidence of potential safety concerns
  - Adult post-market information may provide insight to rare adverse events of particular interest in pediatrics (Stevens-Johnson)

- Adult studies and approval are not required before studying the drug for pediatric use
Pediatric Study Planning & Extrapolation Algorithm

Is it reasonable to assume that children, when compared to adults, have a similar: (1) disease progression and (2) response to intervention?

- No to either
- Yes to both

Is it reasonable to assume similar exposure-response in pediatrics and adults?

- No
- Yes

Is the drug (or active metabolite) concentration measurable and predictive of clinical response?

- No
- Yes

Is there a PD measurement that can be used to predict efficacy in children?

- No
- Yes

Conduct:
(1) Adequate dose-ranging studies in children to establish dosing.
(2) Safety and efficacy trials at the identified dose(s) in children.

"No extrapolation"

"Partial extrapolation"

"Full extrapolation"

Conduct:
(1) Adequate PK study to select dose(s) to achieve similar exposure as adults.
(2) Safety trials at the identified dose(s).

Footnotes:

a. For locally active drugs, includes plasma PK at the identified dose(s) as part of safety assessment.
b. For partial extrapolation, one efficacy trial may be sufficient.
c. For drugs that are systemically active, the relevant measure is systemic concentration.
d. For drugs that are locally active (e.g., intra-luminal or mucosal site of action), the relevant measure is systemic concentration only if it can be reasonably assumed that systemic concentrations are a reflection of the concentrations at the relevant biospace (e.g., skin, intestinal mucosa, nasal passages, lung).
e. When appropriate, use of modeling and simulation for dose selection (supplemented by pediatric clinical data when necessary) and/or trial simulation is recommended.
FDAAA: Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA)

- Extended FDA’s authority to require and request pediatric studies
- Pediatric drug development should begin early in the process (discussed at least by Phase 2)
- Special considerations for pediatric studies
- Under PREA they must address pediatrics
- BUT, if a company wants the financial benefit of increased exclusivity (BPCA) they MUST have a formal Written Request from FDA – and fulfill it.
Remaining Challenges

- **PREA**
  - Has helped tremendously in getting medications approved in children

- **BPCA**
  - Not required by law
  - Expanded indications possible
  - Studies can be more challenging than PREA
  - Balance between increased incentives and utility/feasibility
Geriatric Populations

- Many ways to cut age groups, but most in need of special considerations are > 70 years
- Labeling often provides information at > 65 years
- Most likely of the three populations to be enrolled in Phase 3
- Often do not have separate dosing recommendations (tied to renal function)
Major Organ Functions: None is Isolated

- Renal function
  - Decline with age
  - Higher systemic levels of drugs

- ADME
  - Altered absorption due to gut motility
  - Liver function
  - Higher systemic levels

- CNS function
  - Declines with age
  - Very low reserve
  - Highly sensitive to insult
  - Physical effects (balance, hearing)
  - Psychological effects
Ambien in Geriatrics

• Non-benzodiazepine hypnotic
• Adult dose:
  – 5 mg once daily females
  – 5 or 10 mg once daily for males
  – Can be titrated up to 10 mg
• Elderly/debilitated patients/hepatically impaired: 5 mg once daily
• ADME
  – Cmax, half-life, and exposure increased
  – Converted to inactive metabolites which are then renally eliminated
Geriatric Research Challenges

• Growing population and getting older
  – Increasing need to know
  – The more we look the more we see need

• Unlikely to participate in early trials
  – Dedicated study or Pop PK approach?

• Complications of informed consent, impact of co-morbidities and medications (polypharmacy)

• What is responsible for any observed differences?
Pregnant Women

- Ideally, no drugs would be needed in pregnancy
  - Not realistic
- % of pregnant women on a prescription medication
  - Estimates vary, but probably between 60-90%
- Average age of first time mothers in the US\(^1\)
  - 1970: 21.4 years
  - 2006: 25.0 years
  - Proportion of first time births to women over 35 is 8x what it was in 1970
- Just like everyone else
  - Expect top notch therapy
  - Want information relevant to care
  - “Just tough it out” probably not enough

\(^1\): Figures from CBS news; online story dated 8/14/09
Physiological Changes During Pregnancy

- Increased GFR
- Altered hepatic metabolism
  - P450 changes
  - Biliary
- GI motility slows
- Volume changes begin very early
- All of these affect drug metabolism and PK
- Lab measure and vital sign changes as well

Respiratory rate
Heart rate, BP
pCO2

AST/ALT
Hgb and HCT
Creatinine
Science and the Placenta

- Treating mother’s condition often indirectly benefits fetal/infant outcome
- The human placenta is not a semi-permeable membrane – it is a metabolic organ that makes enzymes and hormones and changes throughout gestation
- The human placenta is structurally and functionally different from those in rodents and rabbits
- The placenta may metabolize drugs & contains drug transporters and efflux pumps
Amoxicillin Dose in Pregnancy

• Average amoxicillin concentration-time profiles for 16 subjects during pregnancy and postpartum

Taken from Andrew et al Clinical Pharmacology and Therapeutics 2007 81(4) pp 547-556
Could This Really Matter?

- Data examples speak for themselves

- **Tetracycline**
  - Antibiotic
  - Causes permanent discoloration of teeth in infants and children when used during pregnancy

- **Thalidomide**
  - Sedative used for morning sickness in late ’50s
  - Withdrawn from market due to teratogenicity and neuropathy
  - Was not approved in the US for morning sickness, but there were thousands of victims worldwide
What About Lactating Mothers? A Case Study.

• Case Study\(^1\): A newborn infant born after an unremarkable pregnancy and delivery (birth weight 3.88 kg) developed difficulty breastfeeding and increased lethargy at 7 days of age. At 11 days of age, he was taken to a pediatrician owing to concerns about his skin color and decreased milk intake. The pediatrician noted that the infant had gained his birth weight. Subsequently on day 13, an ambulance team found the baby cyanotic and without vital signs. Resuscitation was unsuccessful.

• Review of the medical records revealed that the mother was prescribed Tylenol 3 (codeine 30 mg and acetaminophen 500 mg). Initially she took 2 tablets twice daily, but she halved the dose on postpartum day 2 owing to somnolence and constipation.

\(^1\): As reported in Madadi et al Canadian Family Physician 2007 Vol 53 pp 33-35
Case Study Continued

- Analysis of frozen breast milk from the mother revealed an unexpectedly high morphine concentration
- The mother was later determined to be a CYP2D6 ultrarapid metabolizer, which led to excessive conversion of codeine to morphine by the mother
- The morphine was then excreted into the breast milk and consumed by the child
“Should We Study X in Pregnancy?”

• Per the 2004 Draft FDA Guidance on pharmacokinetics in pregnancy:
  – Known to be prescribed or used by pregnant women, especially in 2\textsuperscript{nd} or 3\textsuperscript{rd} trimesters
  – For a new drug or indication, if there is anticipated or actual use in pregnancy
  – Usage is expected to be rare, but the consequences of uniformed doses are great
  – Pregnancy is likely to alter significantly the pharmacokinetics of a drug and any of the above apply
Study Considerations

• Large RCT not practical or usually needed
  – Many other models are useful!
  – Guidance suggests longitudinal or population PK study design

• Knowing the right dose matters
  – Want the highest likelihood of benefit and lowest risk
  – Unique study considerations, but high potential for positive impact

• Double data and monitoring
  – Maternal effects – e.g., hepatic, BP
  – Fetal effects – e.g., growth

• Animal reproductive studies inform study design
  – Some studies seek to determine whether the animal studies are predictive
Where Are We Going?

- Specific populations increasing in number
- Balance between providing treatment and putting vulnerable patients at risk
- As our knowledge increases, we will be better able to address unique concerns
- Investigators must think forward and anticipate
Tools: References

- GrowthCharts
  
  http://www.cdc.gov/growthcharts/

- Vital Signs
  

- Laboratory Values
  
  http://clinicalcenter.nih.gov/ccc/pedweb/pedsstaff/pedlab.html#blo

- Guidance documents
  
  http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm121568.htm